Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

azaCITIDine

azaCITIDine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Vidaza POWDER FOR INJECTION, SUBCUTANEOUS 100 mg      
Onureg TABLET, ORAL 200 mg, 300 mg      
VIEW MORE Antineoplastic Agents
CLASS
100000
Comments:

At Huntsville Main/W&C/Madison, orders for this medication should be rejected and reviewed by an oncology clinical specialist or an oncology pool member (see second page of the document "Hormone Therapies and Guidance on Oral Chemotherapy") 

 

VIDAZA is restricted to oncology.

Initiation of ONUREG should be deferred to outpatient setting. Inpatients may use own supply.

Reviewed: September 28, 2005, Jan 2021 (ONUREG)

Last updated: Aug. 12, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved